All Stories

  1. Are biomarkers expression and clinical-pathological factors predictive markers of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer?
  2. Endometriosis-associated ovarian cancer: a different clinical entity
  3. Sentinel lymph node biopsy in endometrial cancer: When, how and in which patients
  4. Real-time Fluorescent ICG and 99m-Tc Nanocolloid Tracer Navigation in Bilateral Sentinel Lymph Node Mapping of Vulvar Cancer
  5. Low pressure laparoscopic procedure in morbidly obese patients with endometrial carcinoma using a new subcutaneous abdominal wall-retraction device: a surgical challenge
  6. Social media ambassadors and collaboration with OncoAlert: a European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
  7. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study
  8. Diagnostic Accuracy of Magnetic Resonance Imaging in the Pre-Operative Staging of Cervical Cancer Patients Who Underwent Neoadjuvant Treatment: A Clinical–Surgical–Pathologic Comparison
  9. Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review
  10. The neglected role of preimplantation genetic testing for Lynch syndrome
  11. Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer
  12. 2022-RA-959-ESGO Pelvic sentinel lymph nodedistribution; the final outcome of the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
  13. 2022-RA-908-ESGO The importance of pathological ultrastaging for sentinel lymph nodebiopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
  14. Editorial: Molecular influences in therapies in ovarian cancer
  15. Editorial: Future Perspectives of Sentinel Node Mapping in Gynecological Oncology
  16. Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center
  17. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment
  18. Fertility preservation in women with peritoneal surface malignancies: A case series
  19. Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature
  20. 950 Sensitivity and false negativity of SLN frozen sectionhistological evaluation in the sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
  21. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
  22. Correction to: Oocyte cryopreservation in two women with borderline ovarian tumor recurrence
  23. Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer
  24. Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer
  25. Corrigendum to “Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group” [European Journal...
  26. Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis
  27. 558 Fertility-sparing treatment for early stage cervical cancer: a single center experience with conization and nodal evaluation
  28. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group
  29. Fertility preservation in women with cervical cancer
  30. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study
  31. Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media survey
  32. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
  33. Oocyte cryopreservation in two women with borderline ovarian tumor recurrence.
  34. The role of Hysteroscopy in endometrial cancer sentinel node mapping
  35. Corrigendum to “Advances in laparoscopic surgery for cervical cancer” [Crit. Rev. Oncol. Hematol. 143 (August) (2019) 76–80]
  36. Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women
  37. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups
  38. Sentinel Node Mapping in Endometrial Cancer
  39. Advances in laparoscopic surgery for cervical cancer
  40. EP571 Sentinel node mapping in endometrial cancer: analysis of more than 200 cases of hysteroscopic injection of tracers
  41. EP481 Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis
  42. Re: Concordance Between Intracervical and Fundal Injections for Sentinel Node Mapping in Patients With Endometrial Cancer? A Study Using Intracervical Radiotracer and Fundal Blue Dye Injections
  43. Nomogram-based prediction of cervical dysplasia persistence/recurrence
  44. 165 A retrospective study showing the safety of minimally invasive surgery of cervical cancer
  45. Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer
  46. Long-term results of fertility-sparing treatment for early-stage cervical cancer
  47. Oncological outcome of surgical management in patients with recurrent uterine cancer—a multicenter retrospective cohort study—CEEGOG EX01 Trial
  48. Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence
  49. Predictive factors of recurrence in patients with early‐stage epithelial ovarian cancer
  50. Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery
  51. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study
  52. Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved
  53. Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer
  54. Rectus Abdominis Myofascial Flap for Vaginal Reconstruction After Pelvic Exenteration
  55. Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC–IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study
  56. New prophylactics human papilloma virus (HPV) vaccines against cervical cancer
  57. Chemotherapy-related damage to ovarian reserve in childhood cancer survivors: interpreting the evidence
  58. The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer
  59. Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer
  60. Potential impact of introducing a nonavalent HPV vaccination
  61. Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration
  62. Role of bevacizumab in uterine leiomyosarcoma
  63. Ovarian preservation in locally advanced cervical cancer undergoing neoadjuvant chemotherapy and radical surgery
  64. Dose dense neoadjuvant chemotherapy (NACT) with carboplatin-paclitaxel in locally advanced cervical cancer.
  65. Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: A retrospective study of the IRCCS National Cancer Institute of Milan.
  66. LASER treatment for women with high-grade vaginal intraepithelial neoplasia: A propensity-matched analysis on the efficacy of ablative versus excisional procedures
  67. Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction
  68. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment
  69. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
  70. Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
  71. Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer
  72. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer
  73. Locally Advanced Cervical Cancer: Is a Trimodality Treatment a Safe and Effective Approach?
  74. Nerve-Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: A Systematic Review and Meta-Analysis
  75. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?
  76. Regarding “The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy”
  77. Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience
  78. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC–IV Unresectable Ovarian Cancer
  79. Subjective Ultrasound Assessment and the Adnex Model to Differentiate between Benign and Malignant Ovarian Tumors
  80. SENTINEL NODE MAPPING IN ENDOMETRIAL CANCER: A SINGLE CENTER EXPERIENCE OVER 200 CASES OF HYSTEROSCOPIC INJECTION OF TRACERS
  81. POTENTIAL CLINICAL IMPACT OF THE INTRODUCTION OF THE NONAVALENT HUMAN PAPILLOMAVIRUS VACCINATION: AN ANALYSIS OF 13,665 PATIENTS OVER A 18-YEAR STUDY PERIOD
  82. Invasive Paget Disease of the Vulva
  83. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses
  84. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma
  85. The impact of chemotherapy-related leukopenia on survival outcomes in locally advanced cervical cancer
  86. Lymphnode evaluation with SLN procedure after peritumoral injection of tracer with hysteroscopy
  87. Safety and effectiveness of Human Papillomavirus (HPV) vaccination: NCI of Milan position statement
  88. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers
  89. Selecting patients for Laparoscopic interval debulking surgey (IDS) in ovarian cancer
  90. Interpregnancy Interval and Adverse Pregnancy Outcomes
  91. Treatment of Genital Melanoma
  92. Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience
  93. Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging
  94. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
  95. Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer
  96. Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis
  97. Sentinel-lymph-node mapping in endometrial cancer
  98. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy
  99. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology
  100. The association of pre-treatment HPV subtypes with recurrence of VIN
  101. Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia
  102. Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies
  103. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery
  104. Type-specific HPV infection correlates with risk of recurrence of vulvar intraepithelial neoplasia usual type
  105. Sentinel node techinique in endometrial cancer
  106. Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer
  107. Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery
  108. Bulky Mesonephric Adenocarcinoma of the Uterine Cervix Treated with Neoadjuvant Chemotherapy and Radical Surgery: Report of the First Case
  109. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis
  110. 16th Biennial Meeting of the International Gynecologic Cancer Society
  111. Fertility preservation in women with borderline ovarian tumours
  112. Surgical Management and Prognostic Factors of Vulvovaginal Melanoma
  113. Incorporating 3D Laparoscopy for the Management of Locally Advanced Cervical Cancer: A Comparison with Open Surgery
  114. Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women
  115. Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy
  116. Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence
  117. 3D Vision Improves Outcomes in Early Cervical Cancer Treated with Laparoscopic Type B Radical Hysterectomy and Pelvic Lymphadenectomy
  118. Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma
  119. Morcellation of undiagnosed uterine sarcoma: A critical review
  120. FDG-PET/CT to Predict Optimal Primary Cytoreductive Surgery in Patients with Advanced Ovarian Cancer: Preliminary Results
  121. Adult-Onset Cervical Embryonal Rhabdomyosarcoma and DICER1 Mutations
  122. Reply to A Buda
  123. Don't forget the uterus while preserving fertility
  124. Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio
  125. Fertility Sparing Options in Gynecologic Oncology
  126. Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer
  127. Pneumoperitoneum pressures during pelvic laparoscopic surgery: a systematic review and meta-analysis
  128. Incidence of port-site hernia following robotic-assisted sacrocolpopexy
  129. Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience
  130. OC07.05: Application of 3D ultrasound in the assessment of dose-dense NACT efficacy in patients with cervical cancer
  131. When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer
  132. Time for a less radical surgery in cervical cancer after neoadjuvant chemotherapy?
  133. Peritoneal cytology as prognostic factor in cervical cancer
  134. Long-term safety of fertility sparing surgery in early stage ovarian cancer: Comparison to standard radical surgical procedures
  135. OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.
  136. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift
  137. Fertility-Sparing Surgery in Early-Stage Cervical Cancer Patients
  138. Sentinel Node Mapping Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging in Endometrial Cancer Staging
  139. Implementation of laparoscopic approach for type B radical hysterectomy: A comparison with open surgical operations
  140. Treatment of Early Ovarian Cancer
  141. A critical assessment on the role of sentinel node mapping in endometrial cancer
  142. Fertility-sparing surgery in high-risk ovarian cancer
  143. Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma
  144. Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation
  145. Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center
  146. Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial.
  147. Fertility sparing surgery in early stage epithelial ovarian cancer
  148. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva
  149. Embryonal Rhabdomyosarcoma of the Uterine Cervix in Adults
  150. Radical Abdominal Hysterectomy Type B
  151. Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease
  152. The Role of Lymphadenectomy in Cervical Cancer Patients: The Significance of the Number and the Status of Lymph Nodes Removed in 526 Cases Treated in a Single Institution
  153. Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor
  154. Laparoscopic Versus Open Radical Hysterectomy for Stage IB2–IIB Cervical Cancer in the Setting of Neoadjuvant Chemotherapy: A Multi-institutional Cohort Study
  155. Utility of Conization With Frozen Section for Intraoperative Triage Prior to Definitive Hysterectomy
  156. Frozen cone to decide between simple or radical hysterectomy
  157. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer
  158. Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study
  159. Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: Case report
  160. Class III Nerve-sparing Radical Hysterectomy Versus Standard Class III Radical Hysterectomy: An Observational Study
  161. Class III NSRH: Oncological outcome in 170 cervical cancer patients
  162. Sentinel Node Detection in Endometrial Cancer. Diagnostic Accuracy Evaluation
  163. Quality of Life and Sexual, Bladder, and Intestinal Dysfunctions After Class III Nerve-Sparing and Class II Radical Hysterectomies
  164. Nerve-Sparing Radical Vaginectomy
  165. Weekly topotecan and cisplatin (TOPOCIS) as neoajuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II study
  166. Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium
  167. Nerve-sparing radical hysterectomy in cervical cancer: Evolution of concepts
  168. Incidental Diagnosis of Primary Vaginal Adenocarcinoma of Intestinal Type
  169. Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts
  170. Angiokeratoma corporis diffusum (Anderson-Fabry's disease): a case report